Tiziana Life Sciences to Present Intranasal Foralumab at Neuroscience Innovation Forum
I'm PortAI, I can summarize articles.
Tiziana Life Sciences Ltd. will present its lead candidate, intranasal foralumab, at the 9th Annual Neuroscience Innovation Forum on January 11, 2026, in San Francisco. CEO Ivor Elrifi will highlight the anti-CD3 monoclonal antibody aimed at neurodegenerative conditions. Senior management will also engage in one-on-one meetings with investors and stakeholders during the event, which is part of J.P. Morgan Healthcare Conference Week, focusing on advancements in therapeutics and neurotechnology.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments